Clinical Translation of Long-Acting Drug Delivery Systems for Posterior Capsule Opacification Prophylaxis

被引:12
作者
Li, Xinyang [1 ]
Liang, Chen [1 ]
Guo, Yexuan [2 ]
Su, Jing [2 ]
Chen, Xi [1 ]
Macgregor Jr, Robert B. [3 ]
Zhang, Rui Xue [2 ]
Yan, Hong [1 ,2 ]
机构
[1] Northwest Univ, Xian Peoples Hosp, Xian Hosp 4, Shaanxi Eye Hosp,Affiliated Peoples Hosp, 21 Jiefang Rd, Xian 710004, Peoples R China
[2] Northwestern Polytech Univ, Inst Med Res, Xian Key Lab Stem Cell & Regenerat Med, 127 West Youyi Rd, Xian 710072, Peoples R China
[3] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, 144 Coll St, Toronto, ON M5S 3M2, Canada
基金
中国国家自然科学基金;
关键词
drug delivery; PCO; controlled release; pharmacological agent; dosage form; intraocular lens; implant; lens epithelial cell; LENS EPITHELIAL-CELLS; INTRAOCULAR-LENS; SURFACE MODIFICATION; CATARACT-SURGERY; IN-VITRO; SUSTAINED-RELEASE; MITOMYCIN-C; PREVENTION; NANOPARTICLES; PHARMACOKINETICS;
D O I
10.3390/pharmaceutics15041235
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Posterior capsule opacification (PCO) remains the most common cause of vision loss post cataract surgery. The clinical management of PCO formation is limited to either physical impedance of residual lens epithelial cells (LECs) by implantation of specially designed intraocular lenses (IOL) or laser ablation of the opaque posterior capsular tissues; however, these strategies cannot fully eradicate PCO and are associated with other ocular complications. In this review, we critically appraise recent advances in conventional and nanotechnology-based drug delivery approaches to PCO prophylaxis. We focus on long-acting dosage forms, including drug-eluting IOL, injectable hydrogels, nanoparticles and implants, highlighting analysis of their controlled drug-release properties (e.g., release duration, maximum drug release, drug-release half-life). The rational design of drug delivery systems by considering the intraocular environment, issues of initial burst release, drug loading content, delivery of drug combination and long-term ocular safety holds promise for the development of safe and effective pharmacological applications in anti-PCO therapies.
引用
收藏
页数:24
相关论文
共 86 条
  • [1] Ocular Drug Delivery: a Comprehensive Review
    Ahmed, Sadek
    Amin, Maha M.
    Sayed, Sinar
    [J]. AAPS PHARMSCITECH, 2023, 24 (02)
  • [2] Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis
    Akhmetshina, Alfiya
    Palumbo, Katrin
    Dees, Clara
    Bergmann, Christina
    Venalis, Paulius
    Zerr, Pawel
    Horn, Angelika
    Kireva, Trayana
    Beyer, Christian
    Zwerina, Jochen
    Schneider, Holm
    Sadowski, Anika
    Riener, Marc-Oliver
    MacDougald, Ormond A.
    Distler, Oliver
    Schett, Georg
    Distler, Joerg H. W.
    [J]. NATURE COMMUNICATIONS, 2012, 3
  • [3] Posterior Capsular Opacification A Problem Reduced but Not Yet Eradicated
    Awasthi, Niranjan
    Guo, Suqin
    Wagner, B. J.
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2009, 127 (04) : 555 - 562
  • [4] Barry P., 2020, J CATARACT REFR SURG
  • [5] Preserve the (intraocular) environment: the importance of maintaining normal oxygen gradients in the eye
    Beebe, David C.
    Shui, Ying-Bo
    Siegfried, Carla J.
    Holekamp, Nancy M.
    Bai, Fang
    [J]. JAPANESE JOURNAL OF OPHTHALMOLOGY, 2014, 58 (03) : 225 - 231
  • [6] Bertens C.J.F., 2022, COMBINATION DRUG DEL, V1st ed., P47
  • [7] Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation
    Chennamaneni, Srinivas Rao
    Mamalis, Christina
    Archer, Bonnie
    Oakey, Zack
    Ambati, Balamurali K.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2013, 167 (01) : 53 - 59
  • [8] THE PENETRATION OF SORBINIL, AN ALDOSE REDUCTASE INHIBITOR, INTO LENS, AQUEOUS-HUMOR AND ERYTHROCYTES OF PATIENTS UNDERGOING CATARACT-EXTRACTION
    CRABBE, MJC
    PETCHEY, M
    BURGESS, SEP
    HUNG, C
    [J]. EXPERIMENTAL EYE RESEARCH, 1985, 40 (01) : 95 - 99
  • [9] Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Cataract Surgery A Randomized, Placebo-Controlled, Phase III Trial
    Donnenfeld, Eric
    Holland, Edward
    [J]. OPHTHALMOLOGY, 2018, 125 (06) : 799 - 806
  • [10] Synthesis, bioactive properties, and biomedical applications of intrinsically therapeutic nanoparticles for disease treatment
    Duc Dung Nguyen
    Lai, Jui-Yang
    [J]. CHEMICAL ENGINEERING JOURNAL, 2022, 435